Section Menu

890907 | cKK-E12

3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione

cKK-E12

Product is provided for Research Use Only intended for seeking Food and Drug Administration’s (FDA) approval under The Hatch-Waxman Act (formally known as the Drug Price Competition and Patent Term Restoration Act of 1984).

This product is available for shipping within the United States only. International shipping is not available.

This product is synthesized on request. Direct purchase is disabled. Request a quote
Info

cKK-E12

3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione

cKK-E12 is considered a multi-tail ionizable lipidoid and was originally developed to improve the efficacy and safety of siRNA delivery systems. In the original study, cKK-E12 lipid nanoparticle formulations consisting of 50 mol% cKK-E12, 10 mol% cholesterol, 38.5 mol% DSPC, and 1.5 mol% DMG-PEG2000 showed silencing of hepatocytes and high selectivity toward liver parenchymal cells in mice and non-human primates.1

Although cKK-E12 was originally developed for delivery of siRNA, it has proven to also be useful for the delivery of mRNA. Below is a sample of recent research studies conducted using cKK-E12 to deliver mRNA:

  • cKK-E12 mRNA-LNPs were used to engineer dendritic cells ex-vivo for cancer therapies.2
  • mRNA-LNP formulations containing cKK-E12 exhibited efficient T cell expansion and cytokine production ex vivo.3

References:

1.  Y. Dong, K.T. Love, J.R. Dorkin, S. Sirirungruang, Y. Zhang, D. Chen, R.L. Bogorad, H. Yin, Y. Chen, A.J. Vegas, C.A. Alabi, G. Sahay, K.T. Olejnik, W. Wang, A. Schroeder, A.K.R. Lytton-Jean, D.J. Siegwart, A. Akinc, C. Barnes, S.A. Barros, M. Carioto, K. Fitzgerald, J. Hettinger, V. Kumar, T.I. Novobrantseva, J. Qin, W. Querbes, V. Koteliansky, R. Langer, & D.G. Anderson, Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates, Proc. Natl. Acad. Sci. U.S.A. 111 (11) 3955-3960, https://doi.org/10.1073/pnas.1... (2014).

2.  R. Das, X. Ge, F. Fei, S. Parvanian, R. Weissleder, C. S. Garris, Lipid Nanoparticle-mRNA Engineered Dendritic Cell Based Adoptive Cell Therapy Enhances Cancer Immune Response. Small Methods 2025, 9, 2400633. https://doi.org/10.1002/smtd.202400633

3.  Biomater. Sci., 2023,11, 964-974 https://doi.org/10.1039/D2BM01581A

      Data
      Hygroscopic
      No
      Light Sensitive
      No
      Molecular Formula
      C60H120N4O6
      Percent Composition
      C 72.53%, H 12.17%, N 5.64%, O 9.66%
      Purity
      >99%
      Stability
      1 year
      Storage Temperature
      -20°C
      CAS Number
      1432494-65-9
      CAS Registry Number is a Registered Trademark of the American Chemical Society
      Formula Weight
      993.64
      Exact Mass
      992.92
      Downloads

      Related Products

      890908
      306Oi10 306Oi10 Buy Now
      850870
      C12-200 C12-200 Buy Now

      Cart

      Item Price Qty.
      ${ item.sku }
      Base Price: $${ (item.price - (item.options.custompackaging * 4.2 + (item.options.custompackaging > 50 ? 250 : 150))).toFixed(2) }
      Custom Packaging: +${ (item.options.custompackaging * 4.2 + (item.options.custompackaging > 50 ? 250 : 150)).toFixed(2) }
      Change Custom Packaging             		${ item.salePriceAsCurrency }
      Subtotal: ${ cart.itemSubtotal|money }
      ${ adjustment.type }: ${ adjustment.name } ${ adjustment.amountAsCurrency }
      ${ adjustment.name } ${ adjustment.amountAsCurrency }
      Order Total: ${ cart.totalPriceAsCurrency }
      Have a promo code? Enter it in your cart to apply your discount and enjoy the savings on your purchase! Finalize Cart